| Metric | Value (₹ Cr) | vs Q2 FY26 |
|---|---|---|
| Revenue | 35.58 | 31.8% |
| Total Income | 35.78 | 31.5% |
| Expenditure | 25.17 | 36.7% |
| PBT | 10.61 | 14.7% |
| Net Profit | 5.15 | 44.7% |
| OPM | 34.69% | 8.37pp |
| NPM | 14.40% | 3.44pp |
| EPS | 1.13 | 49.1% |
Anlon Healthcare Limited Reports 20x EBITDA Growth and Strongly Positive PAT in Q3 FY26; Completes Strategic Acquisitions
10 Feb 2026 · 10 Feb, 12:24 pm
Summary
Anlon Healthcare Limited, a leading manufacturer of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs), reported strong growth in revenue, profitability, and margins for Q3 and 9M FY26. The growth was supported by robust R&D execution and strategic capacity expansion initiatives. The company also completed strategic acquisitions during the quarter.
Key Highlights
- 1
Total Income for Q3 FY26 was 35.78 crore, representing a YoY growth of 281.5%
- 2
EBITDA at 12.54 crore for Q3 FY26
- 3
Profit After Tax of 5.15 crore for Q3 FY26
- 4
Total Income for 9M FY26 was 121.32 crore, up 69.7% YoY
- 5
EBITDA grew by 115.0% to 32.56 crore for 9M FY26
- 6
PAT rose to 18.02 crore for 9M FY26, resulting in a PAT margin of 14.85%
- 7
Acquired 67.48% equity stake in Apiqo Organics Private Limited for a total consideration of 35.40 crore
- 8
Expected to expand consolidated manufacturing capacity to approximately 1,400-1,600 MTPA by FY26
Management Comments
Mr. Punitkumar Rasadia
We are pleased to report a strong performance during Q3 and 9M FY26, reflecting the strength of our R&D-led growth strategy, expanding API portfolio, and disciplined execution. ... We remain confident of achieving a ~30% revenue CAGR over the next three years, alongside sustainable and gradual improvement in EBITDA margins, while continuing to create long-term value for all stakeholders.
Informational and educational content only. Not investment advice.